Summit & Akeso's Ivonescimab Beats Keytruda in NSCLC Phase 3 | Pharma and Biotech Daily

af Pharma and BioTech Daily

  • 2026-09-04 05:00:00Udgivelsesdato
  • 05:26Varighed